LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Jazz Pharmaceuticals PLC

Open

SectorHealthcare

164.41 1.89

Overview

Share price change

24h

Current

Min

161.93

Max

166.28

Key metrics

By Trading Economics

Income

970M

251M

Sales

80M

1.1B

P/E

Sector Avg

15.775

121.746

EPS

8.13

Profit margin

22.326

Employees

2,800

EBITDA

750M

236M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+34.85% upside

Dividends

By Dow Jones

Next Earnings

24 lut 2026

Market Stats

By TradingEconomics

Market Cap

1.6B

10B

Previous open

162.52

Previous close

164.41

News Sentiment

By Acuity

25%

75%

44 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Jazz Pharmaceuticals PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lis 2025, 12:16 UTC

Major Market Movers

Zymeworks, Jazz Pharmaceuticals Shares Rise Following Positive Phase 3 Results for Cancer Treatment

Peer Comparison

Price change

Jazz Pharmaceuticals PLC Forecast

Price Target

By TipRanks

34.85% upside

12 Months Forecast

Average 222.5 USD  34.85%

High 263 USD

Low 188 USD

Based on 12 Wall Street analysts offering 12 month price targets forJazz Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 111.22Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

44 / 352 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat